Group 1 - The core viewpoint of the article highlights a significant increase in the stock price of Lai Kai Pharmaceutical-B (2105.HK), which surged over 16% to reach a new high of 17.05 HKD in over a month [1] - On November 12, Lai Kai Pharmaceutical granted rights for its breast cancer candidate drug LAE002 (afuresertib) in China to Qilu Pharmaceutical, with a total transaction amount of 2.045 billion RMB [1] - Lai Kai Pharmaceutical is entitled to receive a tiered sales commission ranging from over 10% to over 20% [1] Group 2 - LAE002 is one of the two AKT inhibitors in late-stage clinical development targeting breast and prostate cancer [1] - The Phase III clinical trial (AFFIRM-205) for LAE002, focusing on HR+/HER2- breast cancer, is currently recruiting participants as planned [1] - Lai Kai Pharmaceutical aims to complete participant enrollment for the Phase III trial by Q4 2025 and plans to submit a New Drug Application (NDA) to the CDE in 2026 [1]
港股异动丨来凯医药-B大涨超16%，乳腺癌候选新药获20.45亿元BD大单